Post by Moderna on X
Moderna@moderna_tx
XToday we announced that, in response to a prior Refusal-to-File letter, we engaged with the U.S. Food and Drug Administration (FDA) in a Type A meeting and proposed a revised regulatory approach for our investigational seasonal influenza vaccine candidate, mRNA-1010.
Read more:

188 likes0 repliesPosted Feb 18, 2026